XML 61 R44.htm IDEA: XBRL DOCUMENT
v3.20.2

NOTE 7 – INTANGIBLE ASSETS, NET (Details Narrative) | 9 Months Ended
--- | ---
Sep. 30, 2020 USD ($) Number | Sep. 30, 2019 USD ($)
Finite-Lived Intangible Assets [Line Items] |  |
Write off of patent and trademark costs | $ | $ 584,509 | $ 78,864
Approved Hormone Therapy Drug Candidate Patents [Member] |  |
Finite-Lived Intangible Assets [Line Items] |  |
Finite-Lived Intangible Asset, Useful Life | 20 years |
Domestic US Patents |  |
Finite-Lived Intangible Assets [Line Items] |  |
Number of issued patents | 35 |
Foreign Patents Member |  |
Finite-Lived Intangible Assets [Line Items] |  |
Number of issued patents | 35 |
Domestic Patents BIJUVA |  |
Finite-Lived Intangible Assets [Line Items] |  |
Number of issued patents | 14 |
Foreign Patents BIJUVA |  |
Finite-Lived Intangible Assets [Line Items] |  |
Number of issued patents | 7 |
Domestic Patents Estradiol and Progesterone Candidates |  |
Finite-Lived Intangible Assets [Line Items] |  |
Number of issued patents | 3 |
Domestic US Patents IMVEXXY |  |
Finite-Lived Intangible Assets [Line Items] |  |
Number of issued patents | 10 |
Domestic US Utility Patents IMVEXXY |  |
Finite-Lived Intangible Assets [Line Items] |  |
Number of issued patents | 8 |
Domestic US Design Patents IMVEXXY |  |
Finite-Lived Intangible Assets [Line Items] |  |
Number of issued patents | 2 |
Foreign Patents IMVEXXY |  |
Finite-Lived Intangible Assets [Line Items] |  |
Number of issued patents | 16 |
Foreign Utility Patents IMVEXXY |  |
Finite-Lived Intangible Assets [Line Items] |  |
Number of issued patents | 6 |
Foreign Design Patents IMVEXXY |  |
Finite-Lived Intangible Assets [Line Items] |  |
Number of issued patents | 10 |
Domestic Utility Patent Topical Cream Candidates [Member] |  |
Finite-Lived Intangible Assets [Line Items] |  |
Number of issued patents | 1 |
Domestic Utility Patent Transdermal Patch |  |
Finite-Lived Intangible Assets [Line Items] |  |
Number of issued patents | 1 |
Foreign Utility Patent Transdermal Patch |  |
Finite-Lived Intangible Assets [Line Items] |  |
Number of issued patents | 8 |
Domestic Utility Patent TX009HR |  |
Finite-Lived Intangible Assets [Line Items] |  |
Number of issued patents | 3 |
Domestic Patents Progesterone Formulations |  |
Finite-Lived Intangible Assets [Line Items] |  |
Number of issued patents | 2 |
Foreign Patents Progesterone Formulations |  |
Finite-Lived Intangible Assets [Line Items] |  |
Number of issued patents | 4 |
Domestic Utility Patent Opera |  |
Finite-Lived Intangible Assets [Line Items] |  |
Number of issued patents | 1 |

X
- Definition Number of issued patents. + References No definition available. + Details
Name: | txmd_NumberOfIssuedPatents
Namespace Prefix: | txmd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsBijuvaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsBijuvaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsEstradiolAndProgesteroneCandidatesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSUtilityPatentsImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSDesignPatentsImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentsImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignDesignPatentsImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTopicalCreamCandidatesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTransdermalPatchMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentTransdermalPatchMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTx009HRMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsProgesteroneFormulationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsProgesteroneFormulationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentOperaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |